Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer
Posted inGastroenterology news Oncology

Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer

A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported quality of life without increasing bone pain.
Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?
Posted inGastroenterology news Psychiatry

Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?

The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological improvements and a delayed clinical benefit at 12 months, highlighting the potential for integrated care.
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Posted inClinical Updates Dermatology Gastroenterology Internal Medicine news

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy
Posted inGastroenterology news Oncology Pathology & Lab Medicine

Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy

Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-specific differences across populations. Implications for diagnosis, surveillance, and precision therapy are discussed.
Real-time Sepsis Risk Prediction in Acute Gastrointestinal Bleeding: A Validated Dynamic Monitoring Tool That Improves Early Stratification
Posted inCritical Care Gastroenterology news

Real-time Sepsis Risk Prediction in Acute Gastrointestinal Bleeding: A Validated Dynamic Monitoring Tool That Improves Early Stratification

A multicenter Chinese study developed and validated a real-time nomogram that predicts sepsis in acute gastrointestinal bleeding (AGIB) using clinical and laboratory variables; the tool showed strong discrimination (AUCs 0.827–0.884), good calibration, and an online monitoring platform for dynamic alerts.
Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial
Posted inGastroenterology news Pediatrics

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 weeks, supporting further randomized evaluation.
Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial
Posted inGastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.
Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit
Posted inGastroenterology Infectious Diseases news

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study limitations temper definitive practice change.